BioNTech News

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

Apr 8 17:08 ET

BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Apr 8 07:17 ET

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 25 15:44 ET

BioNTech | 20-F: Registration statement / Annual report / Transition report

Mar 20 08:02 ET

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

Mar 20 07:37 ET

BioNTech | 6-K: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Mar 20 07:17 ET

BioNTech | 6-K: BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Mar 11 09:06 ET

BioNTech | 6-K: BioNTech Announces Planned Retirement of Sean Marett

Mar 7 08:44 ET

BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144

Feb 28 18:29 ET

BioNTech | SC 13D: Statement of acquisition of beneficial ownership by individuals-BioNTech SE(12.5%)

Feb 21 17:07 ET

BioNTech | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Feb 15 16:15 ET

BioNTech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Prof. Ugur Sahin, M.D.(17.4%),Medine GmbH(17.0%)

Feb 14 07:31 ET

BioNTech | 6-K: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 8 06:10 ET

BioNTech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ATHOS KG(43.8%),AT Impf GmbH(43.8%), etc.

Feb 7 17:08 ET

BioNTech | 6-K: Biontech and Dualitybio Receive Fda Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

Jan 31 07:51 ET

BioNTech | 6-K: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

Jan 22 00:00 ET

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

Jan 9 00:00 ET

BioNTech | 144: Notice of proposed sale of securities pursuant to Rule 144

Jan 4 00:00 ET

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

Dec 21, 2023 16:02 ET

BioNTech | 6-K: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Dec 18, 2023 16:22 ET